LNT (Lacto-N-Tetraose) is a highly abundant neutral core HMO in human milk. Some primary known benefits of LNT include reducing infection by inhibiting the adhesion of pathogenic bacteria and their toxins. Also, LNT can positively support gut health by selectively stimulating bifidobacteria.
Regulatory filings for LNT have been made in EU and US and preparation is on way for other major markets.
GlyCare™ LNT will be commercially available from 2020.
HMO help support immunity. Clinical studies have reported a relationship between HMO and immune outcomes in infants. HMO are reported to support an infant’s immune system. HMO may help reduce the risk of infection. HMO may help reduce the risk of certain infections in infants.
Addition of 2’FL/2’FL + LNnT to infant formula* has been clinically reported to help support the immune system. Infant formula containing 2’FL/2’FL + LNnT may help to reduce the incidence of certain (parent-reported) infections and illnesses. Infant formula containing 2’FL + LNnT has been reported to reduce the incidence of (parent reported) respiratory tract infections, anti-fever medication, and antibiotics. Clinical data suggest infant formula with 2’FL/2’FL + LNnT help support immunity.
*HMO in infant formula is dependent on the levels of 2’FL +/- LNnT supplemented into the formula.
Clinical data suggest HMOs support intestinal health in infants. Preclinical and clinical data indicate that HMOs support the growth of beneficial bacteria/bifidobacteria. HMOs may help support the growth of beneficial bacteria/bifidobacteria which are believed to be important for immune and intestinal development and health.
Infant formula with 2’FL and LNnT has been reported to support growth of beneficial bacteria / bifidobacteria. Clinical results indicate that 2’FL + LNnT help bring the intestinal micobiome of formula fed infants closer to that of breastfed infants. 2’FL + LNnT may help bring the intestinal microbiota of infants born by C-section closer to those born vaginally.
Emerging data from pre-clinical models and breast milk studies suggest that HMOs may play a role reducing the incidence of certain allergic manifestations.
An extensively hydrolyzed whey-based formula containing 2’FL and LNnT has been shown to be hypoallergenic.
An extensively hydrolyzed whey-based formula containing 2’FL and LNnT met the AAP criteria for hypoallergenicity.
Note that hypoallergenicity at levels above those studied (1.0 g/L and 0.5 g/L) may need to be assessed.